title: CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells.
abstract: Excessive deposition of fibronectin in the glomerular mesangium in diabetic nephropathy (DN) is partly due to the induction of transforming growth factor-beta (TGF-beta) by high glucose. TGF-beta induces its downstream mediator connective tissue growth factor (CTGF), which stimulates fibronectin matrix synthesis, a process that requires the presence of alpha5beta1 integrin. Although TGF-beta has been shown to upregulate alpha5beta1 integrin expression in human mesangial cells (HMC), little is known about the effect of CTGF on levels of this receptor. This study tested whether CTGF modulates alpha5beta1 expression by HMC in culture and whether changes induced by TGF-beta are mediated through the induction of CTGF. FACS analysis showed that both TGF-beta and CTGF significantly increased cell-surface alpha5beta1 levels compared with basal conditions. RT-PCR indicated that the changes were at the level of transcription. Treatment of cells with TGF-beta and antisense CTGF oligonucleotides significantly reduced the TGF-beta-induced increases in alpha5beta1 levels. CTGF and TGF-beta also significantly increased levels of ligand-occupied cell-surface beta1 integrins and cell adhesion to fibronectin, the main alpha5beta1 substrate. Antisense CTGF significantly reduced the number of adherent cells from TGF-beta-stimulated cultures. Finally, alpha5beta1 blocking antibodies inhibited HMC fibronectin matrix deposition, confirming the importance of this receptor for this process. Taken together, these data provide evidence that CTGF controls alpha5beta1 expression by HMC in vitro. Alterations in alpha5beta1 levels induced by TGF-beta are mediated at least in part through the induction of CTGF, and specific targeting of either alpha5beta1 or CTGF could be useful in controlling excessive fibronectin matrix production in DN.
authors.affiliation: Cell and Molecular Biology Section, Division of Biomedical Sciences, Imperial College School of Medicine, London, United Kingdom.
authors.forename: Benjamin S
authors.initials: BS
authors.lastname: Weston
authors.forename: Nadia Abdel
authors.initials: NA
authors.lastname: Wahab
authors.forename: Roger M
authors.initials: RM
authors.lastname: Mason
mesh_terms: D000906:Antibodies / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects; D002478:Cells, Cultured; D055513:Connective Tissue Growth Factor; D003840:Deoxycholic Acid; D003902:Detergents; D005109:Extracellular Matrix / Q000378:metabolism; D005353:Fibronectins / Q000378:metabolism*; D005920:Glomerular Mesangium / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D017874:Immediate-Early Proteins / Q000494:pharmacology*; D066298:In Vitro Techniques; D039081:Integrin alpha5beta1 / Q000276:immunology / Q000378:metabolism*; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology*; D008024:Ligands; D008934:Mitogens / Q000494:pharmacology*; D012995:Solubility; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000906:Antibodies; C526317:CCN2 protein, human; D003902:Detergents; D005353:Fibronectins; D017874:Immediate-Early Proteins; D039081:Integrin alpha5beta1; D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D008934:Mitogens; D016212:Transforming Growth Factor beta; D003840:Deoxycholic Acid; D055513:Connective Tissue Growth Factor